Browsing Tag
Hepatocellular carcinoma
12 posts
Rznomics gets FDA RMAT status for RZ-001, but can one liver cancer signal carry a platform story?
RNA editing has a regulatory opening in liver cancer. Rznomics now must prove RZ-001 can turn FDA momentum into durable clinical value.
Akeso launches global Phase II trial of cadonilimab for IO-resistant liver cancer patients
Akeso begins a global Phase II trial of cadonilimab in advanced liver cancer. Find out how this bispecific IO drug could reshape second-line HCC therapy.
Sirtex Medical earns FDA nod for SIR-Spheres® Y-90 in treating unresectable liver cancer in U.S.
Sirtex Medical gains FDA approval for SIR-Spheres® Y-90 in treating unresectable hepatocellular carcinoma, expanding its U.S. radioembolization therapy scope.
Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a…
Breakthrough liver cancer treatment: Merck’s new drug combo slashes disease progression risk by 34%
Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have…
NiKang Therapeutics, Roche partner for advanced liver cancer treatment trial
NiKang Therapeutics Inc., a clinical-stage biotech company specializing in small molecule oncology medicines, has announced a significant clinical…
Terumo India introduces advanced liver cancer treatments Occlusafe and LifePearl
Terumo India, the Indian subsidiary of the globally recognized Terumo Corporation, has recently announced the launch of two…
Your diet soda could be deadly: What international agencies say about Aspartame
the International Agency for Research on Cancer (IARC) and the Joint Expert Committee on Food Additives (JECFA), of…
AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study
AstraZeneca’s IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with…
Medivir gets orphan medicinal product designation for MIV-818 for HCC in EU
Swedish biotech company Medivir has secured orphan medicinal product designation from the European Commission for MIV-818 for the…